Dimethyl Fumarate Capsule, Delayed Release
Product Images NDC 70512-852

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Dimethyl Fumarate (NDC 70512-852). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sola Pharmaceuticals, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

70512-852-14 120 mg Carton (70512 852 14 120 mg Carton)

70512-852-14 120 mg Carton (70512 852 14 120 mg Carton)
This appears to be a product description for Dimethyl Fumarate capsules which are delayed-release and come in a bottle with 14 capsules. The recommended usage is to swallow the capsule whole. However, due to the poor quality of the text, some parts are not readable and the description may not be accurate.*
FDA Label Image

70512-852-14 120 mg Label (70512 852 14 120 mg Label)

70512-852-14 120 mg Label (70512 852 14 120 mg Label)
NDC 70512-0852-14 is a medication in the form of delayed-release capsules containing 120mg dimethyl fumarate per capsule. The recommended dosage is one capsule taken orally twice a day. These capsules should be swallowed whole and stored at controlled room temperature, between 20 to 25°C, with excursions permitted to 15 to 30°C. Protect from light and dispense in the original package. This medication is prescription only and comes in a package of 14 capsules. Manufactured for Sola Pharmaceuticals in Baton Rouge, LA.*
FDA Label Image

70512-853-carton 240 mg (70512 853 Carton 240 mg)

70512-853-carton 240 mg (70512 853 Carton 240 mg)
The text appears to be a medicine label. The medication is named "Swallow capsule whale" and comes in delayed-release capsules. It contains 240mg of dmaty umarte per capsule and is to be taken orally. The usual dosage is one to two capsules per day. It is available only with a prescription and comes in a package that includes dosage instructions. The medication should be stored at room temperature and protected from light. The manufacturer is Sol Pharmaceuticals. It is not clear what the medication is used for.*
FDA Label Image

70512-853-label 240 mg (70853 853 60 Label 240 mg)

70512-853-label 240 mg (70853 853 60 Label 240 mg)
This is a medication called dimethyl fumarate, contained in delayed-release capsules. Each capsule contains 240 mg of the medication. The usual dosage is to take one capsule by mouth twice a day. The medication should be stored at 20-25°C (68-77°F) and protected from light. The medication is only available by prescription and the package insert should be consulted for dosage and administration information. These capsules are manufactured by Sola Pharmaceuticals, and the medication comes in a package of 60 capsules.*
FDA Label Image

10 (Dimethyl Fumarate Dr Capsules 1)

10 (Dimethyl Fumarate Dr Capsules 1)
FDA Label Image

Figure (Dimethyl Fumarate Dr Capsules 2)

Figure (Dimethyl Fumarate Dr Capsules 2)
This is a graph showing the percentage of subjects with confirmed progression of disability over time on a study. The X-axis represents the time on study in weeks and the Y-axis represents the percentage of subjects. The study compares the effectiveness of two treatments: Placabo (md08) and Dimetyt fumaratedeayedesense. The note on the graph indicates that confirmed progression of disability is defined as at least a 10 point increase on the EDSS from a baseline EDSS of >=10 confirmed for 12 weeks or at least a 15 point increase on the EDSS from a baseline EDSS of 0 confirmed for 12 weeks. There is additional information contained in the percentages, but without more context, it is not clear what the percentages represent.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.